Stammdaten
Alpha Teknova, Inc. provides critical reagents for life sciences market in the United States and internationally. Its reagents enable the discovery, development, and production of biopharmaceutical products, such as drug therapies, novel vaccines, and molecular diagnostics. The company offers pre-poured media plates for cell growth and cloning; liquid cell culture media and supplements for cellular expansion; and molecular biology reagents for sample manipulation, resuspension, and purification. It serves life sciences market, including pharmaceutical and biotechnology companies, contract development and manufacturing organizations, in vitro diagnostic franchises, and academic and government research institutions. The company was founded in 1996 and is headquartered in Hollister, California.
Unternehmen & Branche
| Name | Alpha Teknova, Inc. |
|---|---|
| Ticker | TKNO |
| CIK | 0001850902 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Drug Manufacturers - Specialty & Generic |
| SIC | 2835 · In Vitro & In Vivo Diagnostic Substances |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 172,6 Mio. USD |
| Beta | 0,33 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | 40,520,000 | -17,259,000 | -0.32 | 103,584,000 | 68,775,000 |
| 2025-09-30 | 10-Q | 10,454,000 | -4,286,000 | -0.08 | 107,625,000 | 72,650,000 |
| 2025-06-30 | 10-Q | 10,287,000 | -3,570,000 | -0.07 | 110,487,000 | 76,057,000 |
| 2025-03-31 | 10-Q | 9,795,000 | -4,645,000 | -0.09 | 113,993,000 | 78,605,000 |
| 2024-12-31 | 10-K | 37,745,000 | -26,745,000 | -0.57 | 118,769,000 | 82,394,000 |
| 2024-09-30 | 10-Q | 9,576,000 | -7,565,000 | -0.15 | 124,099,000 | 87,268,000 |
| 2024-06-30 | 10-Q | 9,614,000 | -5,364,000 | -0.13 | 115,353,000 | 78,928,000 |
| 2024-03-31 | 10-Q | 9,290,000 | -8,097,000 | -0.20 | 120,817,000 | 83,378,000 |
| 2023-12-31 | 10-K | 36,684,000 | -36,780,000 | -1.16 | 128,587,000 | 90,036,000 |
| 2023-09-30 | 10-Q | 8,169,000 | -10,153,000 | -0.34 | 138,385,000 | 99,652,000 |
| 2023-06-30 | 10-Q | 11,527,000 | -7,154,000 | -0.25 | 132,548,000 | 86,208,000 |
| 2023-03-31 | 10-Q | 9,121,000 | -8,817,000 | -0.31 | 141,021,000 | 92,087,000 |
| 2022-12-31 | 10-K | 41,420,000 | -47,468,000 | -1.69 | 152,261,000 | 99,885,000 |
| 2022-09-30 | 10-Q | 10,692,000 | -22,474,000 | -0.80 | 160,272,000 | 111,996,000 |
| 2022-06-30 | 10-Q | 11,690,000 | -6,203,000 | -0.22 | 182,195,000 | 133,467,000 |
| 2022-03-31 | 10-Q | 11,147,000 | -5,497,000 | -0.20 | 184,084,000 | 138,548,000 |
| 2021-12-31 | 10-K | 36,893,000 | -9,803,000 | -0.61 | 166,511,000 | 143,203,000 |
| 2021-09-30 | 10-Q | 9,392,000 | -3,251,000 | -0.12 | 169,163,000 | 146,226,000 |
| 2021-06-30 | 10-Q | 8,313,000 | -2,250,000 | -0.52 | 172,565,000 | 149,035,000 |
| 2021-03-31 | 10-Q | 9,078,000 | -655,000 | 16,288,000 |
Fondsaktivität (Vorquartalsvergleich)
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2026-03-06 | Lowell Matthew | Officer, Chief Financial Officer | Open Market Purchase | 40,000 | 2.19 | 87,616.00 | +142,9% | |
| 2026-03-06 | Gunstream Stephen | Director, Officer, President and CEO | Open Market Purchase | 26,000 | 2.15 | 55,801.20 | +91,0% | |
| 2025-06-27 | DEMSKI MARTHA J | Director | Open Market Sale | -8,000 | 5.06 | -40,512.00 | -66,1% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.